Melanoma overview: Difference between revisions
YazanDaaboul (talk | contribs) |
YazanDaaboul (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Malignant melanoma is the most common fatal skin cancer that arises from the epidermal melanocytes, which are neural crest cells involved in the synthesis of melanin (a brown pigment with photoprotective properties). The prevalence of melanoma is approximately 150-200 per 100,000 individuals. It may be caused by sporadic genetic mutations (e.g. ''[[BRAF]]'' and/or ''[[Ras|N-RAS]]'') or may be part of familial syndromes (e.g. familial atypical multiple mole melanoma syndrome). Melanoma may be classified into either cutaneous or non-cutaneous melanomas. The most common 4 subtypes of cutaneous melanoma include superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Development of melanoma is the result of multiple genetic mutations (multiple hits). The progression to melanoma usually involves the serine-threonine kinases of the [[MAPK/ERK pathway]] (mitogen-activated protein kinase) following mutation of either the ''[[Ras|N-RAS]]'' or ''[[BRAF]]'' oncogene. On gross pathology, the majority of melanomas appear as hyperkeratotic, black-brown, asymmetric [[nodule]]s with irregular borders, but the morphology of the lesion mostly depends on the subtype of melanoma. On microscopic histopathological analysis, each subtype of melanoma has unique characteristic features. The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation. If left untreated, melanoma progression occurs both horizontally (radial growth plate) and vertically (vertical growth plate) and is then followed by dermal invasion and distant metastasis. Common sites of metastasis include [[bone]]s, [[brain]], [[kidney]]s, [[lungs]], [[liver]], and [[skin]] (distant site). The 5-year relative survival of patients with melanoma is highly dependent on the stage at diagnosis. Staging is based on the 2010 AJCC TNM Classification<ref name="pmid19917835">{{cite journal| author=Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al.| title=Final version of 2009 AJCC melanoma staging and classification. | journal=J Clin Oncol | year= 2009 | volume= 27 | issue= 36 | pages= 6199-206 | pmid=19917835 | doi=10.1200/JCO.2009.23.4799 | pmc=PMC2793035 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19917835 }} </ref> and is divided into stage 0 or melanoma in situ, stage I or invasive melanoma with good prognosis, stage II or high-risk melanoma, stage III or melanoma with regional lymph node metastasis, and stage IV or melanoma with distant metastasis. The predominant treatment for primary melanoma is wide excision of the lesion margins. The choice of clinical margins is based on the tumor thickness. When lymph nodes are involved, complete dissection of the nodal basin is recommended. Chemotherapy is indicated for high risk melanomas (stages IIB-IV) as adjuvant therapy and for metastatic disease as first-line therapy. Once diagnosed, follow-up at regular intervals is recommended. | Malignant melanoma is the most common fatal skin cancer that arises from the epidermal melanocytes, which are neural crest cells involved in the synthesis of melanin (a brown pigment with photoprotective properties). The prevalence of melanoma is approximately 150-200 per 100,000 individuals. It may be caused by sporadic genetic mutations (e.g. ''[[BRAF]]'' and/or ''[[Ras|N-RAS]]'') or may be part of familial syndromes (e.g. familial atypical multiple mole melanoma syndrome). Melanoma may be classified into either cutaneous or non-cutaneous melanomas. The most common 4 subtypes of cutaneous melanoma include superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Development of melanoma is the result of multiple genetic mutations (multiple hits). The progression to melanoma usually involves the serine-threonine kinases of the [[MAPK/ERK pathway]] (mitogen-activated protein kinase) following mutation of either the ''[[Ras|N-RAS]]'' or ''[[BRAF]]'' oncogene. On gross pathology, the majority of melanomas appear as hyperkeratotic, black-brown, asymmetric [[nodule]]s with irregular borders, but the morphology of the lesion mostly depends on the subtype of melanoma and amelanotic (no pigmentation) melanomas are not uncommon. On microscopic histopathological analysis, each subtype of melanoma has unique characteristic features. The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation. If left untreated, melanoma progression occurs both horizontally (radial growth plate) and vertically (vertical growth plate) and is then followed by dermal invasion and distant metastasis. Common sites of metastasis include [[bone]]s, [[brain]], [[kidney]]s, [[lungs]], [[liver]], and [[skin]] (distant site). The 5-year relative survival of patients with melanoma is highly dependent on the stage at diagnosis. Staging is based on the 2010 AJCC TNM Classification<ref name="pmid19917835">{{cite journal| author=Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al.| title=Final version of 2009 AJCC melanoma staging and classification. | journal=J Clin Oncol | year= 2009 | volume= 27 | issue= 36 | pages= 6199-206 | pmid=19917835 | doi=10.1200/JCO.2009.23.4799 | pmc=PMC2793035 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19917835 }} </ref> and is divided into stage 0 or melanoma in situ, stage I or invasive melanoma with good prognosis, stage II or high-risk melanoma, stage III or melanoma with regional lymph node metastasis, and stage IV or melanoma with distant metastasis. The predominant treatment for primary melanoma is wide excision of the lesion margins. The choice of clinical margins is based on the tumor thickness. When lymph nodes are involved, complete dissection of the nodal basin is recommended. Chemotherapy is indicated for high risk melanomas (stages IIB-IV) as adjuvant therapy and for metastatic disease as first-line therapy. Once diagnosed, follow-up at regular intervals is recommended. | ||
==Historical Perspective== | ==Historical Perspective== | ||
Revision as of 20:48, 22 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
|
Melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Melanoma overview On the Web |
|
American Roentgen Ray Society Images of Melanoma overview |
Overview
Malignant melanoma is the most common fatal skin cancer that arises from the epidermal melanocytes, which are neural crest cells involved in the synthesis of melanin (a brown pigment with photoprotective properties). The prevalence of melanoma is approximately 150-200 per 100,000 individuals. It may be caused by sporadic genetic mutations (e.g. BRAF and/or N-RAS) or may be part of familial syndromes (e.g. familial atypical multiple mole melanoma syndrome). Melanoma may be classified into either cutaneous or non-cutaneous melanomas. The most common 4 subtypes of cutaneous melanoma include superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Development of melanoma is the result of multiple genetic mutations (multiple hits). The progression to melanoma usually involves the serine-threonine kinases of the MAPK/ERK pathway (mitogen-activated protein kinase) following mutation of either the N-RAS or BRAF oncogene. On gross pathology, the majority of melanomas appear as hyperkeratotic, black-brown, asymmetric nodules with irregular borders, but the morphology of the lesion mostly depends on the subtype of melanoma and amelanotic (no pigmentation) melanomas are not uncommon. On microscopic histopathological analysis, each subtype of melanoma has unique characteristic features. The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation. If left untreated, melanoma progression occurs both horizontally (radial growth plate) and vertically (vertical growth plate) and is then followed by dermal invasion and distant metastasis. Common sites of metastasis include bones, brain, kidneys, lungs, liver, and skin (distant site). The 5-year relative survival of patients with melanoma is highly dependent on the stage at diagnosis. Staging is based on the 2010 AJCC TNM Classification[1] and is divided into stage 0 or melanoma in situ, stage I or invasive melanoma with good prognosis, stage II or high-risk melanoma, stage III or melanoma with regional lymph node metastasis, and stage IV or melanoma with distant metastasis. The predominant treatment for primary melanoma is wide excision of the lesion margins. The choice of clinical margins is based on the tumor thickness. When lymph nodes are involved, complete dissection of the nodal basin is recommended. Chemotherapy is indicated for high risk melanomas (stages IIB-IV) as adjuvant therapy and for metastatic disease as first-line therapy. Once diagnosed, follow-up at regular intervals is recommended.
Historical Perspective
Melanoma was first described by Hippocrates in the 5th century BC. It was often described as the fatal black tumor. In 1838, the term melanoma was first proposed by Sir Robert Carswell, a British pathologist. In 1956, Henry Lancaster, an Australian mathematician, was the first to discover the association between UV radiation exposure and development of melanoma. In 2003, BRAF mutations were first identified in the pathogenesis of melanoma.
Classification
Melanoma may be classified into either cutaneous or non-cutaneous melanomas. The most common 4 subtypes of cutaneous melanoma include superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Less common subtypes of melanoma include desmoplastic/spindle cell melanoma, nevoid melanoma, spitzoid melanocytic melanoma, angiotropic melanoma, blue nevus-like melanoma, and composite melanoma.
Pathophysiology
Malignant melanoma arises from the epidermal melanocytes, which are neural crest cells involved in the synthesis of melanin (a brown pigment with photoprotective properties). Development of melanoma is the result of multiple genetic mutations. The progression to melanoma usually involves the serine-threonine kinases of the MAPK/ERK pathway (mitogen-activated protein kinase) following mutation of either the N-RAS or BRAF oncogene. On gross pathology, the majority of melanomas appear as hyperkeratotic, black-brown, asymmetric nodules with irregular borders, but the morphology of the lesion mostly depends on the subtype of melanoma. On microscopic histopathological analysis, each subtype of melanoma has unique characteristic features. All patients with suspected melanoma require biopsy. Findings on biopsy may distinguish the subtype and the stage of melanoma.
Causes
Melanoma may be caused by sporadic genetic mutations (e.g. BRAF and/or N-RAS) or may be part of familial syndromes (e.g. familial atypical multiple mole melanoma syndrome).
Differential Diagnosis
Melanoma must be differentiated from other causes of skin lesions, such as other skin cancers, premalignant skin tumors, and benign skin lesions.
Epidemiology and Demographics
The prevalence of melanoma is approximately 150-200 per 100,000 individuals. The majority of patients are diagnosed after the age of 65 years. Melanoma is more common among males and individuals of Caucasian race.
Risk Factors
The two most potent risk factors in the development of melanoma are light-colored skin and exposure to ultraviolet radiation. Other risk factors include old age, male gender, family history of melanoma, personal history of skin cancers, immunodeficiency, and certain hereditary disorders.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for skin cancers, including melanoma.[2]
Natural History, Complications and Prognosis
If left untreated, melanoma progression occurs horizontally (radial growth plate) and vertically (vertical growth plate) and is then followed by dermal invasion and distant metastasis. Melanoma is an aggressive tumor characterized by early metastasis. Common sites of metastasis include bones, brain, kidneys, lungs, liver, and skin (distant site). Complications of melanoma are usually related to the site of metastasis. The 5-year relative survival of patients with melanoma is approximately 93%.[3] Features associated with worse prognosis are tumor thickness (Breslow thickness), depth related to skin structures (Clark level), type of melanoma, presence of ulceration, presence of lymphatic/perineural invasion, location of lesion, presence of satellite lesions, and presence of regional or distant metastasis.[4]
Diagnosis
History and Symptoms
Symptoms of melanoma include a rapidly growing existing nevus, non-healing skin ulcers, pruritus, or bone pain.
Physical Examination
Physical examination findings suggestive of malignant melanoma include ABCD: Asymmetry of lesion, Border irregularity, Color change, and large Diameter.
Laboratory Findings
There are no laboratory findings associated with the diagnosis of melanoma. Serum lactate dehydrogenase (LDH) may be elevated among patients with metastasis.
Biopsy
All patients with suspected melanoma require biopsy. Findings on biopsy may distinguish the subtype and the stage of melanoma.
Staging
Staging of melanoma is essential to determine the prognosis. Staging is based on the 2010 AJCC TNM Classification[1] and is divided into stage 0 or melanoma in situ, stage I or invasive melanoma with good prognosis, stage II or high-risk melanoma, stage III or melanoma with regional lymph node metastasis, and stage IV or melanoma with distant metastasis.
Chest X Ray
There are no chest x-ray findings associated with melanoma.
CT
There are no CT scan findings associated with melanoma. Chest CT scan is recommended for diagnosis of metastatic lesions among patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).[5]
MRI
There are no MRI scan findings associated with melanoma. Brain MRI may be considered for diagnosis of metastatic lesions among patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).[5]
Echocardiography or Ultrasound
There are no ultrasound findings associated with melanoma.
Other Imaging Findings
There are no PET scan findings associated with melanoma. Chest PET scan may be considered for diagnosis of metastatic lesions among patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma among patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).[5]
Other Diagnostic Studies
No additional tests are recommended for the diagnosis of melanoma.
Treatment
Medical Therapy
Chemotherapy is indicated for high risk melanomas (stages IIB-IV) as adjuvant therapy and for metastatic disease as first-line therapy. Several single agent and combination regimens have been studied, all with modest impact on survival. All current guidelines still recommend enrollment in clinical trials over current available regimens for patients with metastatic disease. Interferon therapy is the only regimen recommended for adjuvant therapy.
Surgery
The predominant treatment for primary melanoma is wide excision of the lesion margins. The choice of clinical margins is based on the tumor thickness. When lymph nodes are involved, complete dissection of the nodal basin is recommended.
Primary Prevention
Primary prevention of melanoma includes avoidance of sunlight/ultraviolet radiation exposure.[6]
Secondary Prevention
The choice of work-up for secondary prevention of melanoma is based on the stage of melanoma at diagnosis. Secondary prevention includes monthly self-exams, routine dermatologic evaluations, and chest and brain imaging.
References
- ↑ 1.0 1.1 Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR; et al. (2009). "Final version of 2009 AJCC melanoma staging and classification". J Clin Oncol. 27 (36): 6199–206. doi:10.1200/JCO.2009.23.4799. PMC 2793035. PMID 19917835.
- ↑ "USPSTF Skin Cancer Screening". Retrieved 20/8/2015. Check date values in:
|access-date=(help) - ↑ Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
- ↑ Homsi J, Kashani-Sabet M, Messina J, Daud A (2005). "Cutaneous melanoma: prognostic factors". Cancer Control. 12 (4): 223–9. PMID 16258493.Full text (PDF)
- ↑ 5.0 5.1 5.2 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.
- ↑ Edman RL, Wolfe JT (2000). "Prevention and early detection of malignant melanoma". Am Fam Physician. 62 (10): 2277–85. PMID 11126854.